Elissa Peckham Foster, DO
Nephrology · Fort Worth, TXNPI 1356803530
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AstraZeneca at 36.8% of the total. That places this record below the midpoint for nephrology clinicians in TX, where the typical reported total is $1,420.
Across 80 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$667
- Veloxis Pharmaceuticals, Inc.$308
- Amgen$191
- Sanofi$162
- Mallinckrodt Hospital Products Inc.$122
- Otsuka America Pharmaceutical, Inc.$101
- plus $264 from 8 others
What the payments were for
- Food & beverage$1,68593%
- Education$1297%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 36 | $667 |
| Veloxis Pharmaceuticals, Inc. | 11 | $308 |
| Amgen | 8 | $191 |
| Sanofi | 6 | $162 |
| Mallinckrodt Hospital Products Inc. | 3 | $122 |
| Otsuka America Pharmaceutical, Inc. | 4 | $101 |
| Aurinia Pharma U.S., Inc. | 3 | $63 |
| Boehringer Ingelheim | 2 | $48 |
| Travere Therapeutics, Inc. | 2 | $48 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $28 |
| Novartis | 1 | $28 |
| Novo Nordisk | 1 | $18 |
| Nxstage Medical, Inc. | 1 | $16 |
| Recor Medical Inc | 1 | $15 |
How this compares
$1,814 in reported general payments places this provider in the 50th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nifedipine ErNifedipine | 19 | $436 |
| Losartan Potassium | 16 | $96 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Fort Worth
- Saravanan BalamuthusamyFort Worth$435K
- Sandeep ShoriFort Worth$195K
- Michael AragonFort Worth$138K
- Abdul AbdellatifWebster$2.1M
- German HernandezEl Paso$1.3M
- Ankit MehtaDallas$1.1M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Sreedhar MandayamHouston$752K
- Luis VelezSan Antonio$505K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.